Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 28Carboplatin 13Nivolumab 12Cisplatin 12atezolizumab 10Paclitaxel 10venetoclax 9Ipilimumab 9Radiotherapy 8Pemetrexed 8Docetaxel 8fludarabine 7durvalumab 7Specimen Handling 7Gemcitabine 7Cyclophosphamide 7Bevacizumab 7fludarabine phosphate 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6tislelizumab 5enzalutamide 5Trastuzumab 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5tazemetostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × sitravatinib × 90 days × Clear all
NCT04904302 2026-03-20

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡